Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Dec;8(Suppl 5):S466-S468.
doi: 10.21037/tau.2019.10.10.

PD-L1 testing in urothelial carcinoma: are we there yet?

Geert J L H van Leenders  1
Affiliations
Editorial

PD-L1 testing in urothelial carcinoma: are we there yet?

Geert J L H van Leenders. Transl Androl Urol. 2019 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has received research grants from Roche and AstraZeneca relating to PD-L1 testing in urothelial cancer. The author has been participating in advisory board meetings for Roche.

Comment on

References

    1. Suzman DL, Agrawal S, Ning YM, et al. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy. Oncologist 2019;24:563-9. 10.1634/theoncologist.2018-0084 - DOI - PMC - PubMed
    1. Powles T, O'Donnell PH, Massard C, et al. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. JAMA Oncol 2017;3:e172411. 10.1001/jamaoncol.2017.2411 - DOI - PMC - PubMed
    1. Hodgson A, Slodkowska E, Jungbluth A, et al. PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma. Am J Surg Pathol 2018;42:1059-66. 10.1097/PAS.0000000000001084 - DOI - PMC - PubMed
    1. Rijnders M, van der Veldt AAM, Zuiverloon TCM, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. Eur Urol 2019;75:538-40. 10.1016/j.eururo.2018.11.002 - DOI - PubMed
    1. Schwamborn K, Ammann JU, Knuchel R, et al. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays. Virchows Arch 2019. [Epub ahead of print]. 10.1007/s00428-019-02610-z - DOI - PMC - PubMed